Literature DB >> 34677733

A case of hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli after pericardiectomy.

June Tome1, Daniel Barry Maselli2, Roeun Im3, Matthew Brian Amdahl1, Daniel Pfeifle1, Catherine Hagen3, Magnus Halland4.   

Abstract

The majority of cases of Shiga toxin-producing Escherichia coli are self-limited; however, the infection can occasionally be complicated by more severe phenomena, such as thrombotic microangiopathy, with resultant end-organ damage to the kidneys, colon, nervous system, and various other tissues. Shiga toxin-induced hemolytic uremic syndrome (ST-HUS)-the constellation of thrombocytopenia, hemolysis, and renal failure resulting from thrombotic microangiopathy in a subset of infections producing the Shiga toxin-is classically observed in the pediatric population. Nevertheless, the diagnosis should be considered in adults with this presentation, and especially in those with colonic findings suggestive of ischemia. ST-HUS must also be distinguished from other thrombotic microangiopathies and related conditions, such as disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, and complement-mediated HUS, as these diagnoses prompt alternate management strategies. Here, we present a case of ST-HUS in a gentleman following pericardiectomy who was infected with non-O157:H7 E. coli producing Shiga toxin 2.
© 2021. Japanese Society of Gastroenterology.

Entities:  

Keywords:  Microangiopathic hemolytic anemia; Pseudomembranous colitis; Shiga toxin-producing Escherichia coli

Mesh:

Year:  2021        PMID: 34677733     DOI: 10.1007/s12328-021-01539-8

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  1 in total

Review 1.  Pathogenesis of Shiga-toxin producing escherichia coli.

Authors:  Angela Melton-Celsa; Krystle Mohawk; Louise Teel; Alison O'Brien
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

  1 in total
  1 in total

1.  Complementary Sets of Autoantibodies Induced by SARS-CoV-2, Adenovirus and Bacterial Antigens Cross-React with Human Blood Protein Antigens in COVID-19 Coagulopathies.

Authors:  Robert Root-Bernstein; Jack Huber; Alison Ziehl
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.